Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 54

Results For "Development"

4224 News Found

Takara Bio and Resistomap forge deal to speed up global fight against superbugs
News | April 19, 2026

Takara Bio and Resistomap forge deal to speed up global fight against superbugs

The collaboration combines Takara Bio’s large-scale testing technology with Resistomap’s data-driven AMR intelligence


AIG Hospitals Chairman Dr D. Nageshwar Reddy elected to elite AIMBE College of Fellows
People | April 18, 2026

AIG Hospitals Chairman Dr D. Nageshwar Reddy elected to elite AIMBE College of Fellows

Among his notable contributions is the development of the NAGI Stent, a widely adopted device for the drainage of pancreatic pseudocysts


Indian Pharmacopoeia 2026 highlights need for stronger drug standards and global alignment
Policy | April 18, 2026

Indian Pharmacopoeia 2026 highlights need for stronger drug standards and global alignment

Experts highlighted that robust pharmacopoeial frameworks are essential for maintaining the quality, safety and efficacy of medicines


Syntegon reports record FY25 Results; revenue rises 10% to €1.75 billion
Supply Chain | April 17, 2026

Syntegon reports record FY25 Results; revenue rises 10% to €1.75 billion

The company allocated €56 million to research and development for next-generation line solutions


Danone India backs community-led anaemia screening for 1 lakh children in UP
Public Health | April 17, 2026

Danone India backs community-led anaemia screening for 1 lakh children in UP

The programme is being implemented in collaboration with Grow Well Foundation and is expected to expand in a phased manner


Revvity aims to accelerate breakthroughs in cancer research
R&D | April 17, 2026

Revvity aims to accelerate breakthroughs in cancer research

Revvity is positioning its technologies as a connected engine for discovery


Bayer flags major Phase III results for stroke prevention drug asundexian
Clinical Trials | April 17, 2026

Bayer flags major Phase III results for stroke prevention drug asundexian

The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy


NIFTY Pharma shows stable trend amid cautious market sentiment
News | April 17, 2026

NIFTY Pharma shows stable trend amid cautious market sentiment

Muted movement reflects consolidation phase as investors await earnings triggers


OpenAI unveils GPT-Rosalind to accelerate drug discovery for pharma giants
Digitisation | April 17, 2026

OpenAI unveils GPT-Rosalind to accelerate drug discovery for pharma giants

New purpose-built AI model targets faster R&D cycles and deeper scientific insights across life sciences


Morepen Laboratories secures fourth consecutive USFDA ‘NIL 483’ inspection
Drug Approval | April 17, 2026

Morepen Laboratories secures fourth consecutive USFDA ‘NIL 483’ inspection

Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions